Trials / Completed
CompletedNCT01134640
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 286 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final evaluable cases.
Conditions
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-06-02
- Last updated
- 2014-05-09
Locations
15 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01134640. Inclusion in this directory is not an endorsement.